TY - JOUR
AR - GSCR-2021-1-103
TI - Salvage Lymphadenectomy as a Treatment of Prostate Cancer Recurrence
AU - Donghua , Xie
AU - Yanda , LU
AU - Di , Gu
AU - Ming, Lei
AU - Cong , Cai
AU - Wen , Zhong
AU - Defeng , Qi
AU - Wenqi , Wu
AU - Yongda , Liu
AU - Guohua , Zeng
JO - Global Surgery Case Reports
PY - 2021
DA - Thu 11, Mar 2021
SN - 2733-2535
DO - http://dx.doi.org/10.31487/j.GSCR.2021.01.03
UR - https://www.sciencerepository.org/salvage-lymphadenectomy-as-a-treatment-of-prostate-cancer-recurrence_GSCR-2021-1-103 
KW - Salvage lymphadenectomy, prostate cancer, radical prostatectomy, positron emission tomography, biochemical recurrence, biochemical response
AB - Biochemical recurrence (BCR) occurs up to 40% of men who had radical prostatectomy for localized prostate cancer. Regional nodes are usually involved in these cases. Salvage lymphadenectomy (sLND) has been advocated in patients with 'node-only' metastasis with biochemical recurrence, following a definitive treatment of primary prostate cancer. In general, limited case number was reported for each previous study. Four relatively larger reports so far with the highest case number of 189. One randomized controlled study has been completed so far at Phase II level. Salvage LND seems to be safe with relatively low incidence of complications without perioperative mortality. It may postpone adjuvant therapy in selected cases, avoiding systemic side effects and possibly reducing the cost. However, long-term outcome is not very encouraging.